Search Results
Your search for ,USE matches 11186 pages
Showing 3151 - 3200Are Prevalent Cardiovascular Risk Factors Associated With Increased Risk of Subsequent Cancer?
In a study reported in JACC: CardioOncology, Emily S. Lau, MD, of the Cardiology Division, Department of Medicine, Massachusetts General Hospital, and colleagues found that the presence of cardiovascular disease (CVD) risk factors was significantly associated with an increased risk of future...
Virtual Meetings Are Here to Stay
In 2020, the 8th Annual Beirut Breast Cancer Conference (BBCC) was our last in-person meeting. The first cases of COVID-19 started in Lebanon around the end of February 2020, and the pandemic continues into its second year, with waves of rising cases following superspreader events and other likely...
Relationship Between Germline BRCA Pathogenic Variants and Diminished Ovarian Reserve
In a study reported in the Journal of Clinical Oncology, Turan et al found the presence of germline BRCA pathogenic variants was associated with diminished ovarian reserve in young women, particularly in those diagnosed with breast cancer and those with BRCA1 variants. Study Details The individual...
Effect of Oral Chemotherapy Management Program on Capecitabine Toxicity
In a health system retrospective study reported in JCO Oncology Practice, Nhean et al found that implementation of an oral chemotherapy management program was associated with reduced rates of any-grade and severe capecitabine toxicity, less frequent toxicity-related emergency department visits and...
Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?
Recent clinical trials have been encouraging for the neoadjuvant or adjuvant use of immune checkpoint inhibitors in triple-negative breast cancer, but is this approach ready for the clinic? This question was addressed at PER’s Miami Breast Cancer Conference, held virtually this year, by Adam M....
IMagyn050 Trial: Addition of Atezolizumab to Bevacizumab and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer
As reported in the Journal of Clinical Oncology by Kathleen N. Moore, MD, and colleagues, the phase III IMagyn050/GOG 3015/ENGOT-OV39 trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve progression-free survival in patients with newly...
The COVID-19 Pandemic and Cancer Screening Deficits in the United States
In a retrospective cohort study reported in JAMA Oncology, Ronald C. Chen, MD, MPH, and colleagues quantified cancer screening deficits in the United States associated with the COVID-19 pandemic and identified differences in deficits according to region and socioeconomic status. Study Details The...
Imaging Study Aims to Detect Rates of Cancer in Medieval Britain
The first study to use x-rays and computed tomography (CT) to detect evidence of cancer among the skeletal remains of a preindustrial population suggests that between 9% to 14% of adults in medieval Britain had the disease at the time of their death. These findings were published by Mitchell et al...
Contralateral Esophagus-Sparing Radiotherapy Technique Reduces Rates of Esophagitis in Patients With Lung Cancer Receiving High-Dose Chemoradiation
In a small, single-institution phase I trial reported in JAMA Oncology, Kamran et al found that the use of a contralateral esophagus-sparing radiotherapy technique in patients receiving high-dose chemoradiation for locally advanced lung cancer was associated with no cases of grade ≥ 3 esophagitis,...
COVID-19 Pandemic Drove Strategic New Breast Cancer Approaches to Avoid Hospitalization
The COVID-19 pandemic rapidly altered breast cancer treatment approaches, with a significant rise in neoadjuvant endocrine therapy for estrogen receptor–positive tumors, enabling immediate evidence-based treatment of women with an extremely common form of breast cancer, while delaying surgery and...
Health-Related Quality of Life With Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma
As reported in The Lancet Oncology by Andrew Bottomley, PhD, and colleagues, an analysis of the phase III EORTC 1325-MG/KEYNOTE-054 trial showed no clinically significant decline in health-related quality of life (HRQoL) with adjuvant pembrolizumab vs placebo in resected high-risk stage III...
Newly Diagnosed Advanced BRCA-Mutated Ovarian Cancer
In this video, Ursula Matulonis, MD; Joyce F. Liu, MD, MPH; and Bobbie J. Rimel, MD, discuss the use of poly (ADP-ribose) polymerase (PARP) inhibitors in the management of a patient with newly diagnosed, advanced ovarian cancer with a germline BRCA1 mutation. They review recent findings from the...
Chernobyl at 35 Years: An Oncologist’s Perspective
Editor’s note: Dr. Gale is an authority on medical response to nuclear and radiation accidents and participated in rescue efforts at the Chernobyl disaster, as well as at Goiania, Tokaimura, and Fukushima, among other radiation and nuclear accidents. Anyone reading the popular press or even...
ROCK2 Inhibitor Belumosudil for Chronic Graft-vs-Host Disease
In a phase IIa study reported in the Journal of Clinical Oncology, Jagasia et al found that the oral ROCK2 inhibitor belumosudil produced high response rates and reduced corticosteroid use among patients with chronic graft-vs-host disease after allogeneic bone marrow or hematopoietic cell...
AACR and The Mark Foundation for Cancer Research Announce New Grants
The American Association for Cancer Research (AACR) and The Mark Foundation for Cancer Research recently announced five grants to support innovative research focused on understanding the influence of a patient’s biology on the genesis, development, treatment, and survivorship of cancer. Each...
How Interested Are Patients in Integrative Therapies, and How Much Are They Willing to Pay for Them?
The top two barriers to accessing complementary and integrative therapies, according to a survey of 576 patients with cancer and caregivers, were cost, cited by 56%, and a lack of knowledge about the therapies, cited by 52.1%. “Other barriers included a lack of time (29.2%), location of the...
Ethical Considerations Before Launching a Clinical Cancer Trial
Randomized clinical trials are highly regulated initiatives that must comply with multiple requirements while maintaining high epistemic standards, a balance that becomes increasingly difficult as the research questions surrounding immunotherapy and targeted agents become more complex. To shed...
Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma
On February 9, 2021, cemiplimab-rwlc was granted regular approval for the treatment of patients with locally advanced basal cell carcinoma (BCC) who were previously treated with a Hedgehog pathway inhibitor or for whom this type of therapy is not appropriate and granted accelerated approval for...
Brendon Stiles, MD, Named Chief of Thoracic Surgery & Surgical Oncology at Montefiore and Albert Einstein
Leading cardiothoracic surgeon and researcher Brendon Stiles, MD, has been appointed Chief of the Division of Thoracic Surgery & Surgical Oncology in the Department of Cardiothoracic and Vascular Surgery at Montefiore Health System and Albert Einstein College of Medicine. Dr. Stiles will also...
Improvement Programs to Optimize Patient Care for Black Americans With Breast Cancer
Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and White Americans have been selected to participate in ASCO’s quality programs, including the Quality Oncology Practice Initiative (QOPI®)and Quality Training Program...
New ASCO Guideline Offers Recommendations for Neoadjuvant Breast Cancer Treatment
ASCO has released a new guideline regarding the use of neoadjuvant chemotherapy, endocrine therapy, and targeted therapy in breast cancer.1 “This is the first time ASCO has embarked on a guideline for neoadjuvant therapy,” said Larissa A. Korde, MD, of the National Cancer Institute, and guideline...
First-Line Nivolumab/Ipilimumab Plus Chemotherapy Improves Overall Survival vs Chemotherapy in Stage IV or Recurrent NSCLC
As reported in The Lancet Oncology by Luis Paz-Ares, MD, of the Universidad Complutense & CiberOnc, Madrid, and colleagues, the phase III CheckMate 9LA trial has shown improved overall survival with first-line nivolumab/ipilimumab plus two cycles of chemotherapy vs four cycles of chemotherapy...
Expert Point of View: Lisa Baumann Kreuziger, MD, MS
Lisa Baumann Kreuziger, MD, MS, Associate Professor of Hematology/Oncology at Versiti/Medical College of Wisconsin, Milwaukee, introduced Terry B. Gernsheimer, MD, at the Plenary Session and spoke with The ASCO Post about the results of the study. “The investigators of the A-TREAT trial tested a...
Study Finds Tranexamic Acid Unable to Prevent Bleeding in Patients With Hematologic Malignancies
In the first randomized trial to evaluate prophylactic antifibrinolytic therapy in patients with hematologic malignancies, tranexamic acid failed to reduce bleeding or the need for transfusion vs placebo. The study was featured as a Plenary Session during the 2020 American Society of Hematology...
Study Explores Rates of Germline Mutations in Patients With Colorectal Cancer
In a recent study published by Uson Junior et al in Clinical Gastroenterology and Hepatology, researchers found one in six patients with colorectal cancer had an inherited cancer-related genetic mutation, which may be linked to a predisposition to the disease. In addition, the researchers...
Improvement in Survival With Adjuvant Pembrolizumab for Resected Stage III Melanoma
As reported in The Lancet Oncology by Alexander M.M. Eggermont, MD, and colleagues, the pivotal phase III EORTC 1325/KEYNOTE-054 trial has shown significant improvement in the secondary endpoint of distant metastasis–free survival—as well as continued benefit in the primary endpoint of...
Genitourinary Oncology Highlights 2020–2021 Almanac
Landmark changes in the treatment of genitourinary cancers have occurred over the past year, as summarized in this year’s Genitourinary Oncology Almanac from The ASCO Post. Starting with our area of focus, metastatic renal cell carcinoma, the saga continues with two more positive phase III trials...
Effect of Genomic Prostate Score Testing on Choice of Active Surveillance in a Predominantly Black Patient Population
In the ENACT study, reported in the Journal of Clinical Oncology, Murphy et al found that use of the 12-gene Genomic Prostate Score (GPS) in a predominantly Black patient population with relatively low-risk prostate cancer tended to be associated with reduced selection of active...
Effect of Antihypertensive Medications on Risk of Cancer
In an individual participant data meta-analysis of randomized clinical trials reported in The Lancet Oncology, Emma Copland, MSc, and colleagues found “no consistent evidence” of an association between antihypertensive treatment and risk for cancer. A potential increase in risk was observed for...
Immune Checkpoint Inhibitors and Cutaneous Toxicity: Population-Level Analysis
Immune checkpoint inhibitors have transformed treatment for many advanced cancers, but short-term clinical trials and small observational studies have linked the medications with various side effects, most commonly involving the skin. A more comprehensive, population-level analysis now provides a...
To Advance Health Equity, Put Real-World Cancer Data to Work
Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons—like institutional racism and poverty—are a reflection of our broader society. Other inequities may go unrecognized but are no less damaging. People with underlying health...
FDA Pipeline: Recent Designations in Urothelial Cancer, Cervical Cancer, Cholangiocarcinoma, and More
Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for urothelial cancer, cervical cancer, cholangiocarcinoma, solid tumors, and colorectal cancer. Acceptance of Two Supplemental Biologics License Applications for Enfortumab Vedotin-ejfv in...
5-Year Follow-up of SOLO-1: Sustained Benefit for Maintenance Olaparib in Ovarian Cancer
In the 5-year follow-up of the pivotal SOLO-1 trial in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, maintenance treatment with olaparib led to a more than doubling in progression-free survival, according to a presentation at the Society of Gynecologic Oncology (SGO)...
Integration of Brentuximab Vedotin Into Front-Line Treatment for Pediatric Patients With High-Risk Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Metzger et al found that the integration of brentuximab vedotin into front-line treatment of pediatric patients with high-risk classical Hodgkin lymphoma resulted in avoidance of radiotherapy in many patients, as well as high rates of...
Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving Immunotherapy
In an Israeli case-control study reported in a commentary in The Lancet Oncology, Waissengrin et al found that the short-term safety of the Pfizer BNT162b2 mRNA COVID-19 vaccine was similar in patients with cancer receiving immune checkpoint inhibitors compared with healthy controls. Study Details...
Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize different types of head and neck cancers, primarily those that are human...
Estimated Shifts in Cancer Incidence and Death Over Next 2 Decades
In the next 2 decades, rankings of incidence and death across cancer types in the United States will undergo important changes, according to new research published by Lola Rahib, PhD, and colleagues in JAMA Network Open. The study estimates that pancreatic cancer is on course to become the...
Tebentafusp: First Treatment to Improve Overall Survival in Metastatic Uveal Melanoma
Treatment with tebentafusp, a novel bispecific fusion protein, reduced the risk of death from metastatic uveal melanoma at 14 months by half, compared with available treatments, in a phase III study presented by Piperno-Neumann et al at the virtual American Association for Cancer Research (AACR)...
Belzutifan Shows Activity in Advanced Renal Cell Carcinoma, Both as a Single Agent and in Combination Therapy
Separate studies presented at the 2021 Genitourinary Cancers Symposium provide supportive evidence for belzutifan (formerly MK-6482) as an active treatment for metastatic clear cell renal cell carcinoma (RCC). One study showed single-agent activity for this novel approach in an early-phase trial,...
Unselected Autologous Tumor-Infiltrating Lymphocyte Therapy for Metastatic Cutaneous Melanoma
Treatment with unselected autologous tumor-infiltrating lymphocytes (TILs) showed early clinical efficacy among patients with advanced melanoma, according to results presented by Hawkins et al during week 1 of the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 (Abstract ...
Knuckles
The swastikas on his knuckles kept stealing my attention. I tried not to stare but every time he gestured to emphasize his words my gaze snapped back there. That awful symbol, multiplied across all 10 digits, refused to be ignored. The blue lines were blurred and misshapen, probably jail tats. I...
Johan Vansteenkiste, MD, PhD, and Fiona Blackhall, PhD, FRCP, Honored for Lung Cancer Research by ESMO and IASLC
The European Society for Medical Oncology and the International Association for the Study of Lung Cancer recently presented the Heine H. Hansen Award 2021 to Johan Vansteenkiste, MD, PhD, Professor of Medicine at the Catholic University of Leuven and Head of Clinic in the Respiratory Oncology Unit...
Cardiovascular Concerns With the Use of VEGFR Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR) have proved to be effective drugs in the treatment of many solid tumors. However, their clinical benefit may come at the cost of cardiovascular toxicity if clinicians are not vigilant and proactive. During...
Novel Decision-Making Tool for Androgen-Deprivation Therapy for Patients With Prostate Cancer
According to a retrospective study, the combined clinical and cell-cycle risk (CCR) score may be able to accurately predict which patients with intermediate- and high-risk prostate cancer will have little additional benefit from androgen-deprivation therapy added to dose-escalated radiotherapy and...
Association of Community Cancer Centers Names New President
Krista Nelson, MSW, LCSW, OSW-C, FAOSW, was named President of the Association of Community Cancer Centers (ACCC) at the organization’s virtual 47th Annual Meeting and Cancer Center Business Summit. Ms. Nelson will lead the association for the next year, as oncology professionals tackle critical...
Patient-Reported Outcomes With Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma
Results of the CheckMate 9ER phase III trial showed significantly improved patient-reported outcomes in quality of life for first-line treatment with nivolumab plus cabozantinib compared with sunitinib for patients with advanced renal cell carcinoma.1 These findings are in line with the previously...
Yoga in Oncologic Care: An Evidence-Based Treatment to Improve Outcomes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Increasingly, patients with cancer desire nonpharmacologic strategies for managing their...
I’m Living the Life I Was Destined to Have
At 33, I’m not living the life I had imagined for myself. If cancer hadn’t interrupted my plans, I would be serving in the United States Army Special Forces by now, a profession that was inspired by my father’s career as a military officer and helicopter pilot and one that I had dreamed about since ...
End-of-Life Care Remains Aggressive for Patients With Ovarian Cancer
Patients with ovarian cancer frequently receive aggressive end-of-life care despite industry guidelines that emphasize quality of life for those with advanced disease, according to a recent study published by Mullins et al in the journal Cancer. In fact, by 2016, intensive care unit (ICU) stays and ...
Diet and Exercise Intervention May Increase Efficacy of Chemotherapy in Pediatric Patients With Leukemia
Research published by Orgel et al in the journal Blood Advances showed that restricting calories, reducing fat and sugar intake, and increasing physical activity may boost the effectiveness of chemotherapy for older children and adolescents with leukemia. This intervention, which improved...
